Iovance biotherapeutics announces clinical data for ln-145 in non-small cell lung cancer

21.4% overall response rate (orr) in relapsed/refractory metastatic non-small cell lung cancer (mnsclc) patients following one or more prior systemic therapies including immunotherapy
IOVA Ratings Summary
IOVA Quant Ranking